Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GMA-106 is under development for the treatment of type 2 diabetes, obesity and non-alcoholic steatohepatitis (NASH). The drug candidate is being developed based on Bibody platform. It acts by ...

CP-506 is under clinical development by Convert Pharmaceuticals and currently in Phase II for Pancreatic Cancer.

MyMD-1 is under clinical development by TNF Pharmaceuticals and currently in Phase I for Hashimoto Thyroiditis.

Danazol is under clinical development by Viramal and currently in Phase II for Endometriosis. According to GlobalData, Phase II drugs for Endometriosis have a 30% phase transition success rate (PTSR) ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Zigakibart is under clinical development by Novartis and currently in Phase III for IgA Nephropathy (Berger's Disease).

Novaferon is under clinical development by Genova Biotech and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Alintegimod is under clinical development by 7 Hills Pharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate ...

TEV-56192 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Unspecified Immunological Disorders.